GlassScriptPhysician profile
Joanna L Failor
NPI 1922217686
$1,088.98
in general payments reported to CMS, 2019-2025
20 companies · $87.31 in 2025
The $87.31 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $27.79 · 2022: $155 · 2023: $270 · 2024: $373 · 2025: $87.31.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $730.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $221.12 | 2019-2024 | |
| Pfizer INC. | $175.12 | 2019-2024 | |
| Lilly USA, LLC | $89.94 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Astellas Pharma US INC | $85.76 | 2019-2025 | Veozah |
| Glaxosmithkline, LLC. | $85.21 | 2022-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Novo Nordisk INC | $64.63 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $61.17 | 2023-2024 | Farxiga, Airsupra, Breztri |
| Novartis Pharmaceuticals Corporation | $44.55 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $43.70 | 2022-2023 | Dificid |
| E.R. Squibb & Sons, L.L.C. | $29.57 | 2022-2024 | Eliquis |
| Mylan Specialty L.P. | $28.68 | 2022 | |
| Amgen INC. | $24.45 | 2024 | Prolia, Evenity |
| Daiichi Sankyo INC. | $23.75 | 2019 | |
| Sumitomo Pharma America, INC. | $20.15 | 2024 | Gemtesa |
| Shield Therapeutics INC | $18.50 | 2023 | Accrufer |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $15.85 | 2023 | Seglentis |
| Biohaven Pharmaceutical Holding Company LTD. | $15.25 | 2022 | |
| Phathom Pharmaceuticals, INC. | $14.06 | 2024 | Voquezna |
| Idorsia Pharmaceuticals US INC | $13.86 | 2023 | Quviviq |
| Gilead Sciences, INC. | $13.66 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Joanna Failor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.